Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Retrophin, Inc. (NASDAQ: RTRX).

Full DD Report for RTRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: RTRX)

Retrophin's (RTRX) CEO Steve Aselage on Q1 2018 Results - Earnings Call Transcript
Retrophin, Inc. (RTRX) Q1 2018 Earnings Conference Call May 1, 2018 4:30 PM ET Executives Chris Cline - IR Steve Aselage - CEO Neil McFarlane - COO Laura Clague - CFO Bill Rote - SVP and Head of Research and Development Analysts Tim Lugo - William Blair Liisa Bayko - ...
Source: SeekingAlpha
Date: May, 01 2018 21:11
Retrophin beats by $0.31, misses on revenue
Retrophin (NASDAQ: RTRX ): Q1 EPS of -$0.14 beats by $0.31 . More news on: Retrophin, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 01 2018 16:12
Retrophin Reports First Quarter 2018 Financial Results
Company obtains FDA and EMA feedback on pathway to NDA and MAA filing for sparsentan in IgA nephropathy; single Phase 3 trial expected to initiate in the fourth quarter of 2018 Pivotal Phase 3 DUPLEX Study of sparsentan in FSGS underway to support Subpart H NDA filing Revenue rose ...
Source: GlobeNewswire
Date: May, 01 2018 16:01
Institutional Top Ideas Series: Scopia Capital
In the last entry of this series, we took a look at top ideas from DAFNA Capital Management (whose performance practically tripled that of the IBB during the time frame we looked at). Going forward, I hope to continue to delve into the portfolios of successful hedge funds predominantly i...
Source: SeekingAlpha
Date: April, 19 2018 12:12
Retrophin to Report First Quarter 2018 Financial Results
SAN DIEGO, April 17, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report first quarter 2018 financial results on Tuesday, May 1, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial...
Source: GlobeNewswire
Date: April, 17 2018 16:30
New Research Coverage Highlights Woori Bank, Texas Capital Bancshares, Retrophin, SPS Commerce, Corbus Pharmaceuticals, and EnPro Industries - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, April 12, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Woori Bank (NYSE:WF), Texas Capital Bancshares, Inc. (NASDAQ:TCBI), Retr...
Source: GlobeNewswire
Date: April, 12 2018 08:10
Institutional Top Ideas Series: Broadfin Capital
In the last entry of this recently rebooted series, we took a look at top ideas from Deerfield Management (whose performance almost doubled that of the IBB during time frame we looked at). Keep in mind articles older than 10 days can only be accessed if you have a membership to ROTY or S...
Source: SeekingAlpha
Date: April, 05 2018 12:11
Retrophin Initiates Pivotal Phase 3 Clinical Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
SAN DIEGO, April 03, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the first patient has been enrolled in the DUPLEX Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of focal seg...
Source: GlobeNewswire
Date: April, 03 2018 08:00
Aurnia Pharmaceuticals: Creating Value While Executing Its Business Strategy
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) is a Canadian clinical-stage biotechnology company based in Victoria, British Columbia, focused on the development of its lead drug, voclosporin . My last article on Aurinia was published on October 30, 2017, which reported on Aurinia's presen...
Source: SeekingAlpha
Date: March, 20 2018 17:30
Analysis: Positioning to Benefit within Capella Education, Access National, Randgold Resources, Diodes, Silicon Motion Technology, and Retrophin - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Capella Education Company (NASDAQ:CPLA), Access National Corporation (NA...
Source: GlobeNewswire
Date: March, 16 2018 07:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-2128.3228.2428.57927.92234,565
2018-05-1827.2728.1828.3526.8213435,515
2018-05-1726.9227.2727.4726.48244,245
2018-05-1626.6326.8827.0026.51444,812
2018-05-1526.4426.6526.9225.36417,466

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2050,45282,99960.7863Short
2018-08-17102,137125,32481.4984Short
2018-08-1664,62380,20780.5703Short
2018-08-1547,54277,29461.5080Short
2018-08-1438,50574,38451.7652Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RTRX.


About Retrophin, Inc. (NASDAQ: RTRX)

Logo for Retrophin, Inc. (NASDAQ: RTRX)

Retrophin, Inc. OTCQB: RTRX New York based, biotechnology company focused on discovering and developing treatments for rare and life threatening diseases. Retrophin is currently developing treatments for Focal Segmental Glomerulosclerosis FSGS , Pantothenate Kinase Associated Neurodegeneration PKAN , Duchenne Muscular Dystrophy DMD , and Spinal Muscular Atrophy SMA .

 

Contact Information

 

 

Current Management

  • Martin Shkreli / CEO, Founder
  • Marc Panoff / CFO, Chief Accounting Officer
  • Marek Biestek / VP, Fin.
  • Michael Smith / IR
  • Tom Fernandez / IR
  • Stephen Aselage /
  • Steve Richardson /
  • Martin Shkreli /

Current Share Structure

  • Market Cap: $1,051,325,027 - 05/11/2018
  • Authorized: 100,000,000 - 03/05/2013
  • Issue and Outstanding: 39,943,960 - 04/30/2018
  • Float: 8,280,000 - 03/05/2013

 


Recent Filings from (NASDAQ: RTRX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 14 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 01 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 05 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 09 2018

 

 


Daily Technical Chart for (NASDAQ: RTRX)

Daily Technical Chart for (NASDAQ: RTRX)


Stay tuned for daily updates and more on (NASDAQ: RTRX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: RTRX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RTRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of RTRX and does not buy, sell, or trade any shares of RTRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/